MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Insulin Glargine

Selected References:

  • Biocon Biologics Inc. 2023. Semglee Product Label. National Institute of Health DailyMed database. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?. Accessed 1 April 2024.
  • Bruttomesso D, et al. 2011. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). Diabetes Metab. 37(5):426-431.
  • Callesen NF, et al. 2013. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome. J Matern Fetal Neonatal Med. 26(6):588-592.
  • Chico A, et al. 2016. Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin. Eur J Obstet Gynecol Reprod Biol 206: 84-91.
  • de Jong J, et al. 2016. Insulin analogues in pregnancy and specific congenital anomalies: a literature review. Diabetes Metab Res Rev 32(4): 366-375.
  • Di Cianni G, et al. 2005. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Diabetes Care 28:982-983.
  • Di Cianni G, et al. 2008. Perinatal outcomes associated with the use of glargine during pregnancy. Diabet Med. 25(8):993-996.
  • Dolci M, et al. 2005. Use of glargine insulin before and during pregnancy in a woman with type 1 diabetes and Addison’s Disease. Diabetes Care 28:2084-2085.
  • Eli Lilly and Company. 2023. Basaglar Product Label. National Institute of Health DailyMed database. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?. Accessed 1 April 2024.
  • Gallen IW, et al. 2008. Survey of glargine use in 115 pregnant women with Type 1 diabetes. Diabet Med. 25(2):165-169.
  • Holstein A, et al. 2003. Use of insulin glargine during embryogenesis in a pregnant woman with type 1 diabetes. Diabet Med 20:779-780.
  • Imbergamo MP, et al. 2008. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther. 30(8):1476-1484.
  • Lapolla A, et al. 2005. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? Diabetes Metab Res Rev 21:241-52.
  • Lepercq J, et al. 2010. Use of insulin glargine throughout pregnancy in 102 women with type 1 diabetes. Diabetes Metab. 36(3):209-212.
  • Negrato CA, et al. 2010. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract. 89(1):46-51.
  • Pantalone KM, et al. 2011. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study–comment on Negrato et al. Diabetes Res Clin Pract. 93(1):e9-10.
  • Pantalone KM, et al. 2011. Insulin glargine use during pregnancy. Endocr Pract. 17(3):448-55.
  • Pollex E, et al. 2011. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother. 45(1):9-16.
  • Price N, et al. 2007. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG. 114(4):453-457.
  • Sanofi-Aventis U.S. 2022. Lantus Product Label. National Institute of Health DailyMed database. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?. Accessed 1 April 2024.
  • Sonfi-Aventus U.S. 2023. Toujeo Product Label. National Institute of Health DailyMed database. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?. Accessed 1 April 2024.
  • Torlone E, et al. 2007. Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. Eur J Obstet Gynecol Reprod Biol. 132(2):238-239.
  • Woolderink JM, et al. 2005. Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care 28:2594-2595.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.